糖基化终末产物在青光眼中的研究进展  

Research progress of advanced glycation end products in glaucoma

作　　者：韩明月 董洪亮[2] 于金璐 王强 Ming-Yue Han;Hong-Liang Dong;Jin-Lu Yu;Qiang Wang(Department of Ophthalmology,Affiliated Hospital of Binzhou Medical University,Binzhou 256600,Shandong Province,China;Clinical Medical Laboratory,Affiliated Hospital of Binzhou Medical University,Binzhou 256600,Shandong Province,China;Department of Ophthalmology,Yantai Affiliated Hospital of Binzhou Medical University,Yantai 264000,Shandong Province,China)

机构地区：[1]滨州医学院附属医院眼科,中国山东省滨州市256600 [2]滨州医学院附属医院临床医学实验室,中国山东省滨州市256600 [3]滨州医学院烟台附属医院眼科,中国山东省烟台市264000

出　　处：《国际眼科杂志》2020年第6期990-994,共5页International Eye Science

基　　金：山东省科学技术发展计划项目(No.2012YD18117)。

摘　　要：糖基化终末产物(AGEs)体内多种组织中累积,通过调节相关因子表达及激活信号通路等诱发一系列生物学反应,引起年龄相关性疾病及神经退行性病变,如阿尔茨海默病、帕金森病、动脉粥样硬化。青光眼是一种视神经退行性病变,最终导致不可逆的视野缺失,是全球仅次于白内障导致视力丧失的主要原因。青光眼患者视网膜等眼组织中过多AGEs累积,通过激活信号通路、引发生物反应,对组织、细胞的结构及功能造成损伤,参与青光眼发生发展的病理过程。本文主要阐述AGEs在青光眼发病机制、治疗、筛查等相关研究中的最新进展,为青光眼的防治提供新的思路和研究方法。·Advanced glycation end products(AGEs)accumulate in various tissues in the body,and induce a series of biological responses by regulating the expression of related factors and activating signal pathways,causing age-related diseases and neurodegenerative diseases,such as Alzheimer’s disease,Parkinson’s disease and Atherosclerosis.Glaucoma,which is the leading cause of vision loss after cataract worldwide,is a degenerative disease of the optic nerve that ultimately leads to irreversible visual field loss.The accumulation of excessive AGE sin the retina and other eye tissues of glaucoma patients activates signal pathways and triggers biological responses,causing damage to the structure and function of tissues and cells,and participating in the pathogenesis of glaucoma.This article mainly describes the latest progress of AGEs in glaucoma pathogenesis,treatment,screening and other related research,and provides new ideas and research methods for the prevention and treatment of glaucoma.

关 键 词：糖基化终末产物 青光眼 发病机制 青光眼防治 

分 类 号：R74[医药卫生—神经病学与精神病学]